Phase 1 N=34 A Study of LY3009104(Baricitinib) for Healthy Subjects
Healthy Volunteer
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
Healthy
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-020 — 104.182; 44.800; 139.522; 6.012 nanogram per milliliter (ng/mL) — p=<0.001
Phase 1 N=33 Therapeutic Vaccine for HIV
HIV · Therapeutic Vaccine
Primary: The Rate of Related Adverse Events in Subjects Who Began cART During Acute or Early HIV-1 Infection. — 0; 0 Related Adverse Events
Phase 1 N=10 Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children
Complication of Urinary Catheter
Primary: Blood Alcohol Level — 0 Participants
Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
Phase 1 N=80 A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects
Bioequivalence · Fixed Dose Combination Tablets · Healthy Male and Female Subjects
Primary: Area Under Plasma Concentration-time Curve [AUC] Under Fasted or Fed State — 236.3; 248.6; 251.6; 258.2 h*ng/mL
Phase 1 N=55 Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Primary: Dose Limiting Toxicity (DLT) Events in Chemotherapy in Combination With Selumetinib — 3; 7; 4; 3 participants
Phase 1 N=24 Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
Cachexia · Squamous Cell Carcinoma
Primary: Change in Total Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA) From Baseline to 7 Weeks. — -3.31; 1.42 Percent change
Phase 1 N=6 Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
Advanced Malignant Solid Tumors
Primary: Dose Limiting Toxicity (DLT) — 1 participants
Phase 1 N=40 A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 2; 2; 1; 3 participants
Phase 1 N=25 Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)
Renal Insufficiency
Primary: Area Under the Concentration-time Curve of MK-0822 From Time 0 to Infinity (AUC0-∞) After Single Dose — 51.47; 32.12 μM*hr
Phase 1 N=63 Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Neoplasms · Malignant Carcinoma
Primary: Probability of Dose-Limiting Toxicity (DLT) — 0; 12.5; 12.5; 50 percent probability
Phase 1 N=15 A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects
Healthy Subjects
Primary: Effect of Verapamil and the Effect of Itraconazole on the PK of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax). — 385.8; 591.9; 234.1 nmol/L
Phase 1 N=21 A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors
Tumors
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 2 Participants
Phase 1 N=27 A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
Asthma · Chronic Obstructive Pulmonary Disease COPD
Primary: Safety and Tolerability of AZD7594 by Assessment of the Number of Participants With Adverse Events — 3; 1; 1; 5 Pariticpants